【摘要】 目的探讨阿立哌唑治疗难治性精神分裂症的疗效及安全性。方法将65例难治性精神分裂症患者随机分为研究组32例,对照组33例,分别用阿立哌唑及氯氮平治疗,疗程8 w。采用阳性症状与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8 w末研究组有效率为81.3%,显效率28.1%;对照组分别为84.9%和30.3%,两组总体疗效比较无显著性差异(P>0.05);研究组不良反应发生率较低,程度较轻。结论阿立哌唑治疗难治性精神分裂症疗效与氯氮平相当,且安全性高,依从性好。更多还原

【Abstract】 Objective To explore the efficacy and safety aripiprazole in the treatment of refractory schizophrenia.Methods 65 refractory schizophrenics were divided into research group(n=32) took aripiprazole and control group(n=33) did clozapine for 8 weeks.Clinical efficacies were assessed with the Positive and Negative Symptoms Scale(PANSS)and adverse effects with the Treatment Emergent Symptom Scale(TESS).Results Effective and effectual rates were 81.3%and 28.1% in the research group and 84.9% and 30.3% in the control group,respectively,which showed that total efficacies were equivalent(P>0.05).The incidence of adverse effects was lower and degree milder.Conclusion Aripiprazole has equivalent efficacy to clozapine,higher safety and better compliance in the treatment of refractory schizophrenia.更多还原